Search companies or stocks...
NewAmsterdam Pharma Company N.V. (NAMS) intrinsic value snapshot: our valuation models currently suggest the stock is overvalued, with an estimated 165.4% downside relative to fair value at a market price of $35.26. The dollar intrinsic value (fair value) for NewAmsterdam Pharma Company N.V. is derived from DCF, P/E Multiple, and P/S Multiple models—available with Tickerplace Pro for investors comparing market price to modeled fair value.
Current Price: $35.26
Valuation: Overvalued
Confidence: 9.5/10
How we calculate fair value: We combine DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models to estimate intrinsic value. This figure is for information only - not investment advice - and assumptions may not reflect actual market conditions. We encourage doing your own research or speaking with a financial advisor before making investment decisions.
Search our company database (same as the site header), pick a match, or type a ticker to open its intrinsic value analysis.
Based on our intrinsic value models, NewAmsterdam Pharma Company N.V. (NAMS) currently looks overvalued with an estimated 165.45% downside relative to fair value at $35.26. Sign in to Tickerplace Pro to view the full dollar fair value estimate and margin of safety.
NewAmsterdam Pharma Company N.V. (NAMS) fair value vs market price: our valuation models suggest overvalued positioning with an estimated 165.4% downside relative to intrinsic value at a market price of $35.26. The dollar fair value for NewAmsterdam Pharma Company N.V. is calculated from DCF, P/E Multiple, and P/S Multiple models—available with Tickerplace Pro for a full market-price-to-fair-value breakdown and margin of safety.
Our models calculate the intrinsic value of NewAmsterdam Pharma Company N.V. (NAMS) using DCF, P/E Multiple, and P/S Multiple approaches based on projected cash flows, growth rate, and discount rate. Sign in to Tickerplace Pro to view the full dollar estimate.
Based on our 2026 valuation models, NAMS appears overvalued at its current price of $35.26. Our model suggests the stock may be overvalued by 165.4%.
Tickerplace calculates NAMS's intrinsic value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We project future cash flows, apply a discount rate that reflects investment risk, and compare the resulting fair value estimate to the current market price.
Peers for NAMS: open their intrinsic value pages.
